Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01069536

Enrollment

140

Registered

2010-02-17

Start date

2007-03-31

Completion date

2008-05-31

Last updated

2010-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Akathisia, Nausea

Keywords

metoclopramide, akathisia, nausea, vomiting, antiemetic, improvement of nausea

Brief summary

Study Objective: The purpose of this study is to compare the effects of metoclopramide administration in bolus versus slow infusion medications in ED patients complaining of nausea for the determination of the therapeutic effect and prevention of akathisia. Methods: This was a prospective, randomized, double-blind trial. The investigation was held between 01 March 2007 and 01 May 2008, in the Emergency Department of Pamukkale University Faculty of Medicine. The patients with moderate to severe nausea randomized and divided into two groups as for the previously planned administration type of drug. Ten mg metoclopramide was administered in one group with slow infusion (SIG) in 15 minutes, via 2 minutes bolus infusion (BIG) into the other group. Whole procedure was observed, akathisia and nausea scores and vital changes were recorded.

Interventions

DRUGmetoclopramide 10 mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients 18 through 65 years of age and 50-90 kg of weight who presented to the ED with primary or secondary complaints of moderate to severe nausea who not use of commonly accepted antiemetic within the previous 24 hours were eligible for this study. * Their peripheral oxygen saturation level was 90% or over while respirating room air and free of any respiratory problems.

Exclusion criteria

* Patients with mild symptoms of nausea * Altered mental status * Abnormal vital signs * Any known allergy to the metoclopramide * Previously enrolled in the study * Known renal failure or insufficiency * GIS hemorrhage, ileus and/or perforation * Women who were pregnant and lactating * Those with a history of epilepsy * Admitted to the ED due to acute psychiatric symptoms * Restless legs syndrome * Parkinson * Organic brain disease * Phaeochromocytoma * Patient with alcohol * Anticholinergic, sedative, hypnotic, trankilizan, digoxin, cimetidine, tetracycline and levo-dopa use * Presence of severe agitation akathisia can not be evaluated and uncooperative individuals.

Design outcomes

Primary

Measure	Time frame
akathisia and nausea scores	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026